Psychedelics and Psychedelic-Assisted Psychotherapy
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on “psilocybin,” “lysergic acid diethylamide,” “LSD,” “ayahuasca,” “3,4-methylenedioxymethamphetamine,” and “MDMA,” in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms “clinical trial,” “therapy,” or “imaging” in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care. Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as “breakthrough therapies” for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders. Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, comorbid conditions such as suicidality and substance use disorders further complicate research efforts (13, 18, 20, 21).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [21]
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Reiff et al., 2020
In the citing paper
“Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are also novel therapeutics for MDD that show promise in clinical trials [124-126].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [126]
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Ketamine NMDA antagonist Deficits in vigilance, verbal fluency, delayed recall, and tests of frontal lobe function (121) Derealization, depersonalization (8, 120, 121, 124); illusions in all sensory domains and perceptual alterations (121) Amotivation, emotional dulling, hostility (121); anxiety (121, 123) Improved mo…”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Journal of Transpersonal Psychology
(1977) · Journal of Humanistic Psychology · doi:10.1177/002216787701700308 · Cited by 1,732
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 4×
“The mean change in HAM-D score 21 days after drug administration was 211.4. a AASE=Alcohol Abstinence Self-Efficacy Scale; BDI=Beck Depression Inventory; CAPS=Clinician-Administered PTSD Scale; LSD=lysergic acid diethylamide; DMT=N,N-dimethyltryptamine; HADS=Hospital Anxiety and Depression Scale; HAM-A=Hamilton Anxiet…”
BackgroundMethodInfluentialDrug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“(23) conducted an openlabel pilot study evaluating the feasibility and efficacy of”
BackgroundCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Research works printed but not linked: 13
- Lee M, 1992, Acid Dreams: The Complete History of LSD: The CIA, The Sixties, and Beyond
- Darling DC, 2006, Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin Mushroom
- Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
- Abramson HA: The Use of LSD in Psychotherapy, in Transactions of a Conference on d-Lysergic Acid Diethylamine (LSD-25). New York: Josiah Macy Jr. Foundation Publications, 1959
- Grof S, 1977, The Human Encounter With Death
- Labate BC, 2009, Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays
- Holland J, 2001, Ecstasy: The Complete Guide
- Mithoefer MC, 2013, A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder
- Grof S, 2008, LSD Psychotherapy
- Kalant H, 2001, CMAJ, 165, 917
- Preller KH, 2018, Behavioral Neurobiology of Psychedelic Drugs, 221
- Aarde SM, 2017, Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 145
- Heifets BD, JAMA Psychiatry
Cited by
Items 201–300 of 647
David, J., Bouso, J. C., Kohek, M., Oña, G., Tadmor, N., Arnon, T., Dor‐Ziderman, Y., & Berkovich‐Ohana, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1287961 · Cited by 14
“Their potential use as adjuncts for treating various mental health conditions has been recognized (2), with institutions such as the U.S. Food and Drug Administration (FDA), even granting them breakthrough therapy designations (3).”
BackgroundClinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022
Simon, M. W., Olsen, H. A., Hoyte, C. O., Black, J. C., Reynolds, K. M., Dart, R. C., & Monte, A. A. (2024) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2024.06.025 · Cited by 17
Autism, youth suicide, and psychedelics: A review of the 21st century evidence
Chen, M., Su, T., Hsu, J.-W., & Tsai, S. (2024) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001150 · Cited by 16
Posttraumatic Stress Disorder After a Psychedelic Experience, a Case Report
Rubin-Kahana, D. S., Hassan, A. N., & Foll, B. L. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000734 · Cited by 14
“For an excellent recent review about psychedelic-assisted psychotherapy, please see.(7) There are still many open questions about the physical and mental mechanisms behind the effects of psychedelic compounds, and potential therapeutic protocols (ie, specific compounds, dosing).”
BackgroundGlobal bioethical challenges of medicalising psychedelics
McMillan, R. M. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00188 · Cited by 16
Strauss, D., Ghosh, S. B., Murray, Z., & Gryzenhout, M. (2022) · 3 Biotech · doi:10.1007/s13205-022-03355-4 · Cited by 18
Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review
Fonseka, L. N., & Woo, B. K. P. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i5.182 · Cited by 15
Rossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Oña, G., Silveira, G. D. O., Yonamine, M., Bertozi, G., Crevelin, E. J., Queiroz, M. E. C., et al. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001691 · Cited by 13
“These results have also been reported with other psychedelics.(76,77) Because there were no between-group differences, this suggests that the anxiolytic effects were probably caused by ayahuasca and not CBD.”
ResultPresent and future of metabolic and metabolomics studies focused on classical psychedelics in humans
Madrid-Gambín, F., Fabregat‐Safont, D., Gomez‐Gómez, À., Olesti, E., Mason, N. L., Ramaekers, J. G., & Pozo, Ó. J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115775 · Cited by 16
“Successful metab-olomics applications in drugs relevant to psychiatry such as ketamine [60], medical cannabis [61], or MDMA [62 – 64] have been shown to contribute to the therapeutic field.”
Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy
Halman, A., Conyers, R. K., Moore, C., Khatri, D., Sarris, J. J., & Perkins, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3459 · Cited by 19
Mohamed, A., Touheed, S., Ahmed, M., Hor, M., & Fatima, S. (2022) · Cureus · doi:10.7759/cureus.30919 · Cited by 20
“However, they may involve reduced activity in the brain's default mode network and increased functional connectivity between different brain regions [5].”
BackgroundInfluentialMeccia, J., Lopez, J., & Bagot, R. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06297-0 · Cited by 14
Koning, E., & Brietzke, E. M. (2024) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2022-0597 · Cited by 22
“87 Further, the subjective perceptual effects of the psychedelic experience pose a significant challenge to blinding in these studies.”
Ethical considerations in rapid and novel treatments in psychiatry
Haeusermann, T., & Chiong, W. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01635-y · Cited by 13
Visual hallucinations in psychiatric, neurologic, and ophthalmologic disease
Coerver, K. A., & Subramanian, P. S. (2020) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000701 · Cited by 14
The Potential Role of Serotonergic Hallucinogens in Depression Treatment
Psiuk, D., Nowak, E., Cholewa, K., Łopuszańska, U., & Samardakiewicz, M. (2021) · Life · doi:10.3390/life11080765 · Cited by 16
“There are also some medical conditions that exclude participation in psychedelic sessions, including schizoid and paranoid traits or even a family history of schizophrenia [72].”
BackgroundPattern Breaking: A Complex Systems Approach to Psychedelic MedicinePreprint
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2022) · doi:10.31234/osf.io/ydu3h · Cited by 13
Gómez-Busto, F. J., & Ortiz, M. I. (2020) · PubMed Central · doi:10.36131/cnfioritieditore20200606 · Cited by 12
Bader, H., Farraj, H., Maghnam, J., & Omar, Y. A. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i7.908 · Cited by 14
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder
Choi, C. Q., Johnson, D. E., Chen-Li, D. C. J., & Rosenblat, J. D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241286771 · Cited by 16
“It is found in a variety of mushroom species and has been used by Indigenous people in Central and South America (Reiff et al., 2020).”
A pilot human study using ketamine to treat disorders of consciousness
Cardone, P., Bonhomme, A., Bonhomme, V. L., Lejeune, N., Staquet, C., Defresne, A., Alnagger, N., Ezan, P., Lee, M., Piarulli, A., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111639 · Cited by 14
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
“…psilocybin, LSD, and 5-MeO-DMT, DMT is a classic psychedelic and its hallucino-genic effects are believed to occur mainly through 5-HT 2A agonism, although DMT also binds to 5-HT 1A , 5-HT 2C , and 5-HT 1B receptors, serotonin and norepinephrine transporters, and other neurotransmitters [88,111].”
InfluentialZur Komorbidität von Posttraumatischer Belastungsstörung und Sucht in biopsychosozialer Perspektive
Kapfhammer, H. (2021) · Neuropsychiatrie · doi:10.1007/s40211-020-00384-4 · Cited by 12
King, F., & Hammond, R. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200047 · Cited by 14
Shiroma, P. R., Velit-Salazar, M. R., & Vorobyov, Y. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01169-z · Cited by 12
Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness
Holoyda, B. J. (2020) · Psychiatric Services · doi:10.1176/appi.ps.202000213 · Cited by 14
Silveira, G. D. O., Lourenço, F. R., Bruno, V., & Yonamine, M. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.558501 · Cited by 14
“…cells, small peptides, and other organic molecules present in urine specimens that can bind to detector surfaces, which may reduce the LC column lifetime and lead to low sensitivity as well as additional drawbacks generated by matrix effects (Chiu et al., 2010; Rentsch, 2016; Peters et al., 2018).”
BackgroundMcMillan, R. M. (2020) · Journal of Medical Ethics · doi:10.1136/medethics-2020-106619 · Cited by 13
Argento, E., Omene, E., Jaeger, A. H., Kertes, A., Mitchell, K. A., Necyk, C., Thielking, P. D., & Lewis, E. C. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1197409 · Cited by 12
The potential of psilocybin use to enhance well-being in healthy individuals – A scoping review
Wiepking, L., de Bruin, E. J., & Ghiţă, A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00244 · Cited by 14
“As a consequence of promising results, the United States Food and Drug Administration (FDA) granted “ breakthrough therapy ” status to the use of psilocybin for treatment-resistant depression (Reiff et al., 2020).”
BackgroundBarnett, B. S., Koons, C. J., den Eynde, V. V., Gillman, P. K., & Bodkin, J. A. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2368617 · Cited by 13
“…is accumulating evidence for the efficacy of psychedelic-assisted therapy in the treatment of post-traumatic stress disorder, depression, and other psychiatric conditions, psychedelics have not been approved by the US Food and Drug Administration for treatment of any condition (Reiff et al. 2020).”
Psilocybin in pharmacotherapy of obsessive-compulsive disorder
Owe-Larsson, M., Kamińska, K., Buchalska, B., Mirowska-Guzel, D. M., & Cudnoch‐Jędrzejewska, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00633-1 · Cited by 15
“A number of clinical trials reported that psilocybin used in depression and MDMA used in PTSD are safe and effective as add-on treatments [ 31 , 32].”
BackgroundSutherland, I., Ho, M., & Croarkin, P. E. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0082 · Cited by 12
“A 2020 review in the American Journal of Psychiatry identi fi ed 14 “ well-designed clinical trials ” investigating LSD, MDMA, psilocybin, and ayahuasca (Reiff et al., 2020).”
Lapid, M. I., Pagali, S. R., Randall, A., Donovan, K. A., Bronars, C. A., Gauthier, T. A., Bock, J., Lim, S. D., Carey, E. C., Sokolowski, E. I., et al. (2025) · Palliative & Supportive Care · doi:10.1017/s147895152500032x · Cited by 13
““Classical psychedelics,” including psilocybin, lysergic acid diethy-lamide, N,N-dimethyltryptamine, and mescaline, share this mechanism of action but also have complex pharmacologic action at several other receptor sites as well (Kwan et al. 2022; Nichols 2016; Reiff et al. 2020).”
Elsilä, L. V., Korhonen, N., Hyytiä, P., & Korpi, E. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.602770 · Cited by 12
“During the last 2 decades, there has been a new surge of enthusiasm of psychedelic drugs in the fields of psychiatry and neuroscience (Reiff et al., 2020).”
BackgroundA continuum hypothesis of psychotomimetic rapid antidepressants
Haarsma, J., Harmer, C. J., & Tamm, S. (2021) · Brain and Neuroscience Advances · doi:10.1177/23982128211007772 · Cited by 13
“Indeed, psychedelics, and to some extent ketamine, are often used in combination with psychotherapy, supporting this view (Carhart-Harris et al., 2016, 2018a; de Osório et al., 2015; Dore et al., 2019; Reiff et al., 2020).”
BackgroundInfluentialvan der Gronde, T., Los, L., Herremans, A. H. J., Oosting, R. S., Zorzanelli, R., & Pieters, T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00412 · Cited by 13
Argento, E., Christie, D., Mackay, L., Callon, C., & Walsh, Z. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.716593 · Cited by 13
Perspectives in Psychopharmacology
(2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19106 · Cited by 11
Palliative care in severe mental illnesses
Masel, E. K., Antunes, B., & Schulz-Quach, C. (2023) · BMC Palliative Care · doi:10.1186/s12904-023-01152-1 · Cited by 17
Batievsky, D., Weiner, M. D., Kaplan, S. B., Thase, M. E., Maglione, D. N., & Vidot, D. C. (2023) · Frontiers in Pain Research · doi:10.3389/fpain.2023.1127863 · Cited by 15
“The process of creating connections between neurons is often completely compromised for individuals suffering from depression, so the increased synaptogenesis and neuroplasticity works to promote restoration of those lost neural connections and reverse any stressinduced neuronal changes (14).”
BackgroundNorred, M. A., Zuschlag, Z. D., & Hamner, M. B. (2024) · Drugs · doi:10.1007/s40265-023-01983-5 · Cited by 17
“…believed to be mediated by a number of mechanisms, including monoamine release, serotonin and NE transporter reuptake inhibition, monoamine oxidase inhibition, partial agonism of serotonin receptors (5-HT 2A , 5-HT 1A , and 5-HT 2C receptors), and increase in blood concentrations of oxytocin [121].”
Woollacott, M. H., Riddle, J., Hermansson, N., Sacchet, M. D., & Ingram, D. M. (2024) · EXPLORE · doi:10.1016/j.explore.2024.103056 · Cited by 13
The Epidemiology of Psychedelic Use Among United States Military Veterans
Davis, A. K., Bates, M. J., Lund, E. M., Sepeda, N. D., Levin, A. W., Armstrong, S. B., Koffman, R. L., Hooyer, K., & Yehuda, R. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2401977 · Cited by 12
“Although current evidence for PAT is not yet sufficient for approval by the Food and Drug Administration (FDA), two psychedelic drugs have been given “breakthrough therapy status” by the FDA, possibly leading to approval in the coming years (Reiff and Widge 2020).”
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research
O’Donnell, K. C., Grigsby, J., & Grob, C. S. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230785 · Cited by 11
Barnett, B. S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221123051 · Cited by 10
Fissler, P., Vandersmissen, A., Filippi, M., Mavioğlu, R. N., Scholkmann, F., Karabatsiakis, A., & Krähenmann, R. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231164707 · Cited by 11
“In the animal studies, the cells were exposed to the 5-HT2 receptor agonists for 24 h or even 6 days (Fanibunda et al., 2019), whereas in clinical and research practice, patients usually receive one to three moderate-to-high doses of the psychedelic substance (Reiff et al., 2020).”
BackgroundHerrmann, Z. M., Levin, A. W., Cole, S. P., Slabaugh, S., Barnett, B. S., Penn, A., Jain, R., Raison, C. L., Rajanna, B., & Jain, S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0030 · Cited by 12
“34 Psychedelics are a broad class of consciousness changing agents characterized by an ability to engender deeply meaningful, psychologically insightful, and mys-tical-type experiences (e.g., connection to the universe or nature and sense of awe) in many users, particularly when taken in supportive…”
Card, K. G., Grewal, A., Closson, K., Martin, G., Baracaldo, L., Allison, S., Kruger, D. J., & Walsh, Z. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2268640 · Cited by 13
“This hope has resulted in an explosion of clinical investigations about psilocybin and other psychedelics (Kurtz et al. 2022) and the U.S. Food and Drug Administration has identified psilocybin as a “breakthrough therapy” (Reiff et al. 2020).”
Song-Smith, C., Jacobs, E., Rucker, J., Saint, M., Cooke, J. E., & Schlosser, M. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-083595 · Cited by 12
The Resurgence of Hallucinogen Drugs in Clinical Research
Rivera-Garcia, M. T., & Cruz, S. L. (2023) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.23000108 · Cited by 16
“Although hallucinogen drugs use is well documented in ancient cultures for religious and recreational common 15,16 .”
BackgroundHallucinations and Hallucinogens: Psychopathology or Wisdom?
Bouso, J. C., Oña, G., Kohek, M., SANTOS, R. G. D., Hallak, J. E. C., Alcázar‐Córcoles, M. Á., & Obiols‐Llandrich, J. (2023) · Culture Medicine and Psychiatry · doi:10.1007/s11013-022-09814-0 · Cited by 15
Bryson, N., Alexander, R., Asnis-Alibozek, A. G., & Ehlers, M. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00058 · Cited by 9
Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies
Barstowe, A., & Kajonius, P. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424272 · Cited by 12
“A review by Reiff et al. (2020) has shown that most studies on the therapeutic use and effects of psychedelics are written in English, but it is important to keep in mind that this observation is based on a limited sample of studies and may not be representative of the entire body of research on…”
Berlowitz, I., Pesantes, M. A., Palacios, C. C., Martin-Söelch, C., Wolf, U., & Maake, C. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003912 · Cited by 15
Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review
Chen, M. J. Q., Chen-Li, D. C. J., Chisamore, N., Husain, M. I., Vincenzo, J. D. D., Mansur, R. B., Phan, L., Johnson, D. E., McIntyre, R. S., & Rosenblat, J. D. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116532 · Cited by 11
Fryc, M., Kluzik, D., Czopek, A., Jończyk, J., & Zagórska, A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110622 · Cited by 10
IsHak, W. W., Hirsch, D., Renteria, S., Totlani, J., Murphy, N., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Keerthana, S., et al. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07141-3 · Cited by 13
IsHak, W. W., García, P., Pearl, R., Dang, J., William, C., Totlani, J., & Danovitch, I. (2023) · PubMed Central · Cited by 14
Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review
Chisamore, N., Kaczmarek, E. S., Le, G. H., Wong, S., Orsini, D. K., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00319-8 · Cited by 9
“Research into the psychiatric use of serotonergic psychedelics dates back to the 1950s and 1960s, but strict government oversight limited the progression of research in psychedelics from the 1970s until recently [8, 9].”
Lemos-Santos, P., Blumrich, L., Debia, J. B., Castaldelli-Maia, J. M., Suen, P. J. C., & Malbergier, A. (2023) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2022.0493.r1.150623 · Cited by 14
Attitudes of European psychiatrists on psychedelics: a qualitative study
Žuljević, M. F., Breški, N., Kaliterna, M., & Hren, D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1411234 · Cited by 8
“…psychedelic-assisted psychotherapy (PAP) involve 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as “ breakthrough therapies ” for posttraumatic stress disorder and treatment-resistant depression, respectively (6).”
BackgroundJunges, L. H., & Müller‐Santos, M. (2024) · Biotechnology Progress · doi:10.1002/btpr.3513 · Cited by 10
The Drug Abuse Screening Test (DAST): First 40 Years and Future Developments
Skinner, H. A., Samadi, S., Khan, S. B., & Crowley, L. (2024) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000222 · Cited by 11
The serotonergic psychedelic DOI impairs deviance detection in the auditory cortex
Horrocks, M., Mohn, J. L., & Jaramillo, S. (2024) · Journal of Neurophysiology · doi:10.1152/jn.00411.2024 · Cited by 8
Karp, E., Rubinstein, Z., Abend, R., Lev‐Ran, S., Naor, L., & Mikulincer, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251334025 · Cited by 10
“…highlights the therapeutic potential of psy-chedelic compounds, such as classic psychedelics (e.g., lysergic acid diethylamide (LSD), psilocybin) and 3,4-methylenedioxym-ethamphetamine (MDMA), for post-traumatic stress disorder (PTSD) (e.g., Ko et al., 2023; Reiff et al., 2020; Smith et al., 2023).”
Regulatory Challenges of Integrating Psychedelics into Mental Health Sector
Soylemez, K. K., de Boo, E. M., & Lusher, J. M. (2025) · Psychoactives · doi:10.3390/psychoactives4020011 · Cited by 13
Zhang, Y., Yang, L., Zhang, Q., Li, C., Mao, F., & Zhuo, C. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03410-7 · Cited by 10
“The U.S. Food and Drug Administration (FDA) has classi fi ed psilocybin as a “ breakthrough therapy ” for treatment-resistant depression [21, 22], and this psychedelic has been shown to produce rapid, long-lasting antidepressant effects [18, 23, 24].”
Avanceña, A. L. V., Vuong, L., Kahn, J. G., & Marseille, E. A. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03556-4 · Cited by 10
“In an effort to develop new MDD treatments, psychedelic therapies have been tested in randomized clinical trials (RCTs) for their ef fi cacy in reducing MDD symptoms [12, 13].”
EMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Neuroscience and addiction research: current advances and perspectives
Darcq, E., & Kieffer, B. L. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02763-5 · Cited by 11
“…preclinical evidence supporting the therapeutic potential of epidrugs, in connection with another emerging treatment approach, i.e. the use psychedelics that attracts increasing interest in addiction therapies, and more generally in psychiatric research (Reiff et al. 2020 ; Rucker et al. 2018).”
Barnett, B. S. (2025) · Psychoactives · doi:10.3390/psychoactives4010004 · Cited by 8
“The therapeutic potential of psychedelics for psychiatric and substance use disorders has generated significant scientific interest in recent decades [1–4].”
Psychothérapie augmentée par la kétamine (KAP) dans les troubles de l’humeur : mode d’emploi
Bottemanne, H., Baldacci, A., Muller, C., Boyreau, A., & Claret, A. (2021) · L Encéphale · doi:10.1016/j.encep.2021.08.011 · Cited by 13
The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice
Stein, C. A., Penn, A., Hope, S., Dorsen, C. G., & Mangini, M. (2022) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13371 · Cited by 10
Turkia, M. (2022) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2022.100029 · Cited by 18
Exline, J. J., Schutt, W. A., Pait, K. C., & Wilt, J. A. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2148062 · Cited by 8
“This is especially true when psychedelics are used alongside traditional therapy techniques (Reiff et al., 2020).”
BackgroundTang, Z.-H., Yu, Z., Li, Q., Zhang, X., Muhetaer, K., Wang, Z., Xu, P., & Shen, H. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06366-y · Cited by 9
“Particularly, encouraging results have been reported with major depression, substance addiction, obsessive–compulsive disorder (OCD), post-traumatic stress disorder, and autism spectrum disorder in the last decade (Carhart-Harris and Goodwin 2017; Reiff et al. 2020).”
BackgroundGlynos, N. G., Baker, A., Aday, J. S., Kruger, D. J., Boehnke, K. F., Lake, S., & Lucas, P. (2025) · British Journal of Pain · doi:10.1177/20494637251319497 · Cited by 8
Biased Signaling in Psychedelic Action
Wacker, D., & McCorvy, J. D. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-012545 · Cited by 10
Wittenkeller, L. M., Gudelsky, G. A., Winhusen, T. M., & Amato, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70181 · Cited by 10
“Since then, psilocybin-assisted psychotherapy has been tested in clinical studies as a potential treatment intervention for SUDs and other psychopathologies (Reiff et al., 2020).”
Rudzki, S. J. (2022) · Military Medicine · doi:10.1093/milmed/usac095 · Cited by 8
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician
Garakani, A., Alexander, J. L., Sumner, C. R., Pine, J. H., Gross, L. S., Raison, C. L., Aaronson, S. T., & Baron, D. A. (2023) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000729 · Cited by 7
Development of the Japanese version of the 30‐item Mystical Experience Questionnaire
Yonezawa, K., Tani, H., Nakajima, S., & Uchida, H. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12377 · Cited by 6
Trainees Unprepared for Advances in Psychedelic Medicine: A Survey Study
Geller, J. A., Glynos, N. G., Lemmen, A., Pacilio, R. M., Kruger, D. J., & Hosanagar, A. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2341795 · Cited by 8
“Research in this area, after gaining traction in the mid-20 th century, was limited for several decades after psyche-delic compounds were classified as Schedule I substances in 1970, thus deemed absent of any clinical utility (Reiff et al. 2020).”
Malpractice and Other Civil Liability in Psychedelic Psychiatry
Holoyda, B. J. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220528 · Cited by 7
Haye, W. D. L., Walcott, G. O., Eaton, J., Beckford, J., & Greene, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1136990 · Cited by 8
“While the exact mechanisms by which psilocybin and other psychedelics augment the psychotherapeutic experience are still unclear, it is thought that they catalyze or enhance psychotherapeutic processes (30).”
BackgroundDimitrova, A., Milia, M. G. D., Rensi, R., Grassi, S., Gualco, B., & Vaiano, F. (2023) · Separations · doi:10.3390/separations10090502 · Cited by 8
Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets
de Sousa, T. R., Rema, J., Machado, S. E. D. C., & Novais, F. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211201145800 · Cited by 8
Penn, A., & Yehuda, R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0017 · Cited by 8
Albert, A. E., & Back, A. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1529427 · Cited by 6
“Moreover, comorbid conditions such as suicidality and substance use disorders further complicate research efforts (13, 18, 20, 21).”
Muir, O. S., Shinozuka, K., Beutler, B. D., Arenas, A., Cherian, K. N., Evans, V. D., Fasano, C., & Tabaac, B. J. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001720 · Cited by 7
Ferreira, A. E., & Reis-Pina, P. (2024) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2024.112020 · Cited by 6
Gaughan, S. J., Wootton, A. R., Krantz, D., Davis, A. K., James, J. E., Rinaldi-Rose, R., Lancelotta, R., & Sevelius, J. M. (2025) · International Journal of Transgender Health · doi:10.1080/26895269.2025.2478112 · Cited by 8
“PAT combines psychedelic drug dosing with psychotherapy, involving preparatory sessions, supervised substance use enhanced by auditory and visual stimuli, and post-experience integration with trained psychotherapists (Reiff et al., 2020).”
Calnan, M., Blest‐Hopley, G., Busch, C., Adams, M., Ruffell, S., Piper, T., Roseman, L., Kettner, H., & Carhart-Harris, R. L. (2025) · Brain and Behavior · doi:10.1002/brb3.70660 · Cited by 10
“2017; Reiff et al. 2020) and improving general psychological well-being (Mans et al. 2021).”
Aparicio‐Terrés, R., López‐Mochales, S., Díaz‐Andreu, M., & Escera, C. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15403 · Cited by 11
Chwyl, C., Wilson‐Poe, A. R., Hoffman, K. A., Bazinet, A. D., Pertl, K., Luoma, J. B., Jarlais, D. C. D., Bielavitz, S., & Korthuis, P. T. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104938 · Cited by 7
Ulisse, K., Albitar, J., Aromin, J. T., & Berry, J. H. (2025) · Brain Sciences · doi:10.3390/brainsci15090980 · Cited by 9
Žuljević, M. F., Mijatović, A., Orhanović, R., Goasdoué, G., & Gujinović, D. (2026) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2026.112170 · Cited by 8
Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations
Palmisano, V. F., Agnorelli, C., Fagiolini, A. M., Erritzøe, D., Nutt, D. J., Faraji, S., & Nogueira, J. J. (2024) · Biochemistry · doi:10.1021/acs.biochem.3c00598 · Cited by 10
Is music a drug? How music listening may trigger neurochemical responses in the brain
Reybrouck, M., & Dyck, E. V. (2024) · Musicae Scientiae · doi:10.1177/10298649241236770 · Cited by 17
“The use of psilocybin , in particular, has been explored (Reiff et al., 2020) and psilocybin-assisted psychotherapy is currently used as an established research protocol for safe drug administration in combination with psychological support as a clinical intervention (Carhart-Harris et al., 2016;…”
Metadata
- Authors
- Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R.
- Affiliations
- Emory University (US)
- Department of Psychiatry, New York University School of Medicine, New York (Reiff); Department of Psychiatry and Human Behavior, Emory University School of Medicine, Atlanta (Richman, McDonald); Department of Psychiatry, Dell Medical School and the Institute for Early Life Adversity Research, University of Texas at Austin (Nemeroff); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, R.I. (Carpenter); Department of Psychiatry and Behavioral Sciences, University of...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2020-05-01
- Volume
- 177
- Issue
- 5
- Pages
- 391-410
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3006905788
- Cited by
- 649
- References
- 120
- Citations by year
- 2026: 93 · 2025: 126 · 2024: 129 · 2023: 113 · 2022: 102 · 2021: 60 · 2020: 26
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG059307)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, psychedelic-assisted psychotherapy, psilocybin, LSD, ayahuasca, MDMA, post-traumatic stress disorder, treatment-resistant depression, cancer-related anxiety, substance use disorders, trauma and stress-related disorders, end-of-life care
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin, Psychotherapy, N-Methyl-3,4-methylenedioxyamphetamine, Evidence-Based Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.